Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.

ABSTRACT: The marine habitat has produced a significant number of very potent marine-derived agents that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of cases, in both in vivo murine models and in humans. Although many agents have entered clinical trials in cancer, to date, only Cytarabine, Yondelis® (ET743), Eribulin (a synthetic derivative based on the structure of halichondrin B), and the dolastatin 10 derivative, monomethylauristatin E (MMAE or vedotin) as a warhead, have been approved for use in humans (Adcetris®). In this review, we show the compounds derived from marine sources that are currently in clinical trials against cancer. We have included brief discussions of the approved agents, where they are in trials to extend their initial approved acti

SUBMITTER: Newman DJ 

PROVIDER: S-EPMC3917273 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature